newsfilter
← Latest News
PR Newswire·

ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update

  • LOTIS-5 Phase 3 topline data is expected in the second quarter of 2026, with full data for LOTIS-5 & LOTIS-7 anticipated by year-end 2026.
  • Fourth quarter 2025 net product revenue was approximately $22.3 million, while full year 2025 revenue was $73.6 million.
  • Cash & cash equivalents stood at $261.3 million as of December 31, 2025, providing a runway of at least 2028.
  • The Company amended its HealthCare Royalty financing agreement in February 2026 to increase strategic flexibility, reducing the change of control payment cap from $750 million to $150 million through 2027.
  • LOTIS-5 topline results are anticipated in Q2 2026 following the pre-specified number of 262 progression-free survival events, with a potential sBLA submission in mid-2027 if data is positive.
  • LOTIS-7 trial data showed an 89.8% best overall response rate & 77.6% complete response rate across 49 evaluable patients, with full data expected by end of 2026.
  • Research & development expenses decreased to $104.0 million for the full year 2025 from $109.6 million in 2024, driven by reduced spending on discontinued programs.
  • Net loss for the full year 2025 was $142.6 million, or $1.12 per share, compared to a net loss of $157.8 million, or $1.62 per share, in 2024.
  • Adjusted net loss for the full year 2025 was $91.7 million, or $0.72 per share, compared to $111.4 million, or $1.15 per share, in 2024.
  • ADC Therapeutics hosted a conference call on March 10, 2026, at 8:30 a.m. EDT to discuss fourth quarter & full year 2025 financial results.
  • The Company revised its prior period financial statements to correct the classification of inventory balances between current & long-term assets, with no impact on total assets or net loss.
  • A $100 million PIPE financing in June 2025 & a $60 million PIPE financing in October 2025 contributed to strengthening the cash position, raising $150.8 million in total.
  • Full results for LOTIS-7 & investigator-initiated trials in follicular lymphoma & marginal zone lymphoma are expected to be published between late 2026 & mid-2027.